慢性丁型肝炎565例纵向分析:病程与临床结局
基于D-SOLVE和HDV-1000多中心回顾性数据库,纳入565例随访≥3年的慢性丁型肝炎患者,中位随访55个月。随访期间48例进展为肝硬化,47例发生肝脏相关事件;高龄、GGT升高、肝硬化及可检测HDV RNA是肝脏相关结局的主要决定因素,HDV RNA≥1000 IU/mL时风险增加。
要点
- 慢性丁型肝炎患者中,可检测HDV RNA与肝脏相关事件风险显著相关(aHR=10.32)。
- 基线GGT升高与肝硬化发生(aHR=2.77)及肝脏相关事件(aHR=4.38)均显著相关。
- HDV RNA≥1000 IU/mL时肝脏相关事件风险增加,而HBsAg水平与疾病进展无关。
核心结论
- 在大型真实世界慢性丁型肝炎队列中,高龄、GGT升高、肝硬化和可检测HDV RNA是肝脏相关结局的主要决定因素,HDV RNA≥1000 IU/mL时预后更差。
研究设计与样本
- 多中心回顾性队列研究,纳入D-SOLVE和HDV-1000数据库(6个欧洲中心)中随访≥3年的慢性丁型肝炎患者565例。
- 分析生化和实验室标志物的纵向变化,采用时间-事件分析,并以单变量和多变量Cox回归评估肝脏相关事件的预测因素。
主要发现
- 中位随访55个月期间,48例进展为肝硬化,1、3、5年累积发生率分别为1.8%、5.6%、13.6%。
- 47例(9%)发生新发肝脏相关事件,1、3、5年累积发生率分别为0.8%、2.4%、10.8%。
- 基线抗-HCV阳性(aHR=1.72,95%CI 1.22-5.88)和GGT升高(aHR=2.77,95%CI 1.22-6.27)与肝硬化发生显著相关。
- 高龄(aHR=1.03,95%CI 1.00-1.07)、GGT升高(aHR=4.38,95%CI 1.81-10.57)、可检测HDV RNA(aHR=10.32,95%CI 1.34-79.53)和肝硬化诊断(aHR=2.23,95%CI 1.03-4.84)与肝脏相关事件相关。
- HDV RNA≥1000 IU/mL时肝脏相关事件风险增加,HBsAg水平与疾病进展无关。
临床怎么用
- 对慢性丁型肝炎患者应监测HDV RNA和GGT,尤其HDV RNA≥1000 IU/mL提示肝脏相关事件风险增加。
- 合并抗-HCV阳性或基线肝硬化的患者需加强肝硬化及肝脏相关事件的监测。
局限性
- 本研究为回顾性队列研究,来自6个欧洲中心,可能存在选择偏倚和信息偏倚。
- 部分亚组事件数较少,如可检测HDV RNA与肝脏相关事件关联的95%CI较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis delta (CHD) causes severe chronic viral hepatitis. OBJECTIVE: This study examines the predictors and outcomes of CHD course in a large contemporary cohort. DESIGN: CHD patients with ≥3 years follow-up from the multicentre retrospective D-SOLVE and hepatitis D virus (HDV)-1000 database (6 European centres) were enrolled. Longitudinal changes in biochemical and laboratory markers were analysed. Time-to-event analysis was performed and predictors of liver-related events (LREs) were assessed with univariable and multivariable Cox regression analysis. RESULTS: Among a total of 1004 patients, 565 (56%) with ≥3 years follow-up were included. Patients had a mean (SD) age of 45 (12) years, with 55% men and 60% of European origin. At baseline, 77.8% were HDV RNA+, 39.8% had cirrhosis and 45% had previous interferon therapy. During a median (IQR) follow-up of 55 (46-62) months, 48 patients progressed to cirrhosis at 1, 3 and 5-year cumulative incidence of 1.8%, 5.6% and 13.6%, respectively. De-novo LREs occurred in 47 (9%) patients at 1, 3 and 5-year cumulative incidence of 0.8%, 2.4% and 10.8%, respectively. Cox regression analysis showed that anti-hepatitis C virus+ (adjusted hazard ratio (aHR)=1.72, 95% CI 1.22 to 5.88) and elevated gamma-glutamyl transferase (GGT) (aHR=2.77, 95% CI 1.22 to 6.27) at baseline were significantly associated with cirrhosis onset, while older age (aHR=1.03, 95% CI 1.00 to 1.07), elevated GGT (aHR=4.38, 95% CI 1.81 to 10.57), detectable HDV RNA (aHR=10.32, 95% CI 1.34 to 79.53) and cirrhosis diagnosis (aHR=2.23, 95% CI 1.03 to 4.84) correlated with LREs. The risk for LREs increased from HDV RNA ≥1000 IU/mL, while hepatitis B surface antigen (HBsAg) levels did not correlate with disease progression. CONCLUSIONS: In a large real-life cohort of CHD patients, older age, GGT elevation, cirrhosis and detectable HDV RNA were the main determinants of liver-related outcomes, with worse prognosis noted from HDV RNA ≥1000 IU/mL.
引用
- Kamal H, Degasperi E, Radu M, et al. Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia. Gut. 2026. PMID: 42309805. doi:10.1136/gutjnl-2025-336234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。